Aims: To assess the proliferative activity of gestational trophoblastic disease (GTD) using one of the novel proliferation markers (MCM7) and to determine its prognostic value in hydatidiform mole (HM). Methods and results: Immunohistochemical staining for MCM7 was performed on 122 samples of paraffinembedded trophoblastic tissues including 22 normal first-trimester placentas, 12 term placentas, 12 spontaneous miscarriages (SM), 21 partial moles (PM), 44 complete hydatidiform moles (CM), and 11 choriocarcinomas (CCA). The correlations between the proliferative indices assessed by MCM7, proliferating cell nuclear antigen (PCNA) and Ki67 (MIB1) immunoreactivity as well as clinical progress were assessed. MCM7 immunoreactivity was found predominantly in the nuclei of cytotrophoblast and intermediate trophoblast and decreased with placental maturation. MCM7 expression was highest in CCA, followed by CM, PM, normal firsttrimester placenta, SM and term placenta. MCM7 index was significantly higher in PM and CM than in SM (P ¼ 0.007, P < 0.001) but not between PM and CM themselves (P ¼ 0.560). Eighteen of the 65 patients with HM developed persistent trophoblastic disease (PTD) requiring chemotherapy. There was no significant difference in MCM7 indices between the patients who developed PTD and those who did not (P ¼ 0.312). MCM7 indices correlated well with Ki67 (P ¼ 0.002) but not with PCNA (P ¼ 0.054) indices. MCM7 indices demonstrated less variability than PCNA and Ki67 and may be a better proliferation marker than the latter two. Conclusions: We conclude that MCM7 is useful in differentiating molar and non-molar gestations but is not helpful in discriminating PM from CM or in predicting PTD.
Introduction
Gestational trophoblastic disease (GTD) encompasses a heterogeneous group of lesions characterized by abnormal proliferation of trophoblast and is classified as partial mole (PM), complete mole (CM), invasive mole, choriocarcinoma (CCA), placenta site trophoblastic tumour and epithelioid trophoblastic tumour. 1, 2 The latter three are true neoplasms, whereas PM and CM represent abnormal placentas prone to neoplastic transformation. A distinction between a molar gestation versus a non-molar miscarriage should be made, because 8-30% of women with molar pregnancies will develop persistent trophoblastic disease (PTD) requiring chemotherapy. PTD is characterized by persistent or rising human chorionic gonadotropin (hCG) levels after suction evacuation. With no alternative markers available, the hCG hormone titres remain the most reliable and specific prognostic indicator for the management of patients with molar pregnancies.
Quantitative assessment of immunoreactivity for proliferating cell nuclear antigen (PCNA) and Ki67 antigen (MIB1) is the most frequently used method for the study of cell proliferation in cancer. Most previous reports on these two markers suggest that Ki67 is useful and may be better than PCNA in the differential diagnosis of GTD. [3] [4] [5] [6] [7] [8] Staining for PCNA can be associated with technical challenges and is limited to fixed, paraffin-embedded tissues. 9 Moreover, PCNA is an auxiliary protein for DNA polymerase d that may be involved not only in DNA replication but also in DNA repair mechanisms. 10, 11 The quantitative relationship between PCNA expression and proliferation may be lost in some circumstances. 12 Although superior to PCNA as a proliferation marker, Ki67 also has recognized limitations and its accurate function is largely unknown. There is evidence to suggest that Ki67 is not a key molecule directly responsible for cell proliferation but plays a role in ribosome biosynthesis. 13, 14 Thus, detecting proteins directly regulating DNA replication may be a more accurate way of reflecting tumour proliferation. 15 The minichromosome maintenance (MCM) proteins are a family of highly conserved proteins essential for initiating and regulating DNA replication in all eukaryotic cells. 16 All six members of the MCM proteins, MCM2 to MCM7, function as heterohexameric complexes which are necessary for DNA replication and represent a convergence point for many signalling pathways involved in cell growth. In vitro studies have shown that these proteins are expressed in proliferating cells but not in quiescent or differentiated cells, making them specific indicators of cell proliferation. 15, 17, 18 Recently, antibodies to the MCM proteins have become available and have been used to define the proliferative compartments in both normal and abnormal human tissues. [18] [19] [20] [21] [22] In addition, all six MCM members have been confirmed to produce similar immunostaining results in a variety of tissue sections. 19 MCM protein expression has not been characterized previously in GTD. In this study, we have investigated one of these proteins, MCM7, in a large archival series of GTD to determine whether it is a good marker for differentiating molar and non-molar pregnancy and to determine whether it is of potential prognostic value for predicting PTD.
Materials and methods

selection of cases
The pathology reports of patients with a diagnosis of PM, CM and CCA from the Department of Pathology, University of Hong Kong, Queen Mary Hospital were reviewed. Twenty-one PM (gestational age 8-20 weeks), 44 CM (gestational age 7-25 weeks) and 11 CCA were retrieved randomly. The histological features of these cases were assessed in haematoxylin and eosin (H&E)-stained sections using generally agreed and accepted diagnostic criteria. In addition, 22 first-trimester placentas (gestational age 7-11 weeks), 12 term placentas (gestational age 38-41 weeks) and 12 spontaneous miscarriages (6-12 weeks) were also retrieved from the files and included in this study for comparison. The cases of spontaneous miscarriage (SM) showed hydropic changes. These cases have been included in our previous studies on Ki67 and PCNA. 5, 6 Clinical follow-up data were available in the patients with either PM or CM. PTD was diagnosed if there was a plateau in hCG level for 4 weeks or if there was a further increase in hCG for three consecutive weeks when pregnancy was excluded. 23 According to these criteria, 47 patients had spontaneous regression of their hydatidiform moles, while 18 developed PTD and required chemotherapy.
immunohistochemical staining
The most representative paraffin block of each case was selected for immunohistochemical study. Sections 5 lm thick were cut and mounted on 2% aminopropyltriethoxysilane-coated glass slides. To avoid antigen loss after preparation, immunostaining was carried out within 48 h. Immunohistochemistry was performed using the streptavidin-biotin complex immunoperoxidase method (Dako, Glostrup, Denmark). After microwave pretreatment for antigen retrieval, a monoclonal mouse antibody for MCM7 (Oncogene Research Products, Boston, MA, USA) was applied at a dilution of 1 : 100 and incubated overnight at 4°C. Biotin-labelled anti-mouse immunoglobulin (Ig)G (Vector Laboratories, Burlingame, CA, USA) was used as the secondary antibody and 3,3-diaminobenzidine-hydrogen peroxide as chromogen. Sections were counterstained with haematoxylin, then dehydrated, cleared and mounted. To ensure consistency of MCM7 staining between batches, a known positive control, breast carcinoma, was included in each batch. The experiment was repeated if there was any fluctuation in the MCM7 index of this control.
Negative control was prepared by replacing the primary antibody with Tris-buffered saline.
assessment of mcm7 index
Sections were examined at high power (· 400) and 20 fields per section were chosen at random. A minimum of 1000, usually 2000-3000, trophoblastic cells were counted in each case, with the aid of an eyepiece graticule. A quantitative estimate of nuclear labelling index for MCM7 immunoreactivity (MCM7 index) was made by scoring positive nuclei as a percentage of the total number of nuclei counted. Decidua, myometrium, fetal tissue and other tissues found in the sections were excluded from the analysis. The nuclei were scored as positive or negative without regard to staining intensity. Ten cases from each category were counted by two pathologists (A.N.Y.C. and W.C.X.) to estimate interobserver variation.
statistical analysis
Statistical analysis was performed using the Statistical Package for Social Science 10.1 for Windows (SPSS Inc., Chicago, IL, USA). Numerical data not in a normal distribution were analysed by the Mann-Whitney test and analysis of variance. Correlation analysis was performed using the v 2 test. A P-value <0.05 was taken as significant.
Results
The MCM7 immunoreactivity was confined to the nuclei and was predominantly found in the cytotrophoblast and intermediate trophoblast in all the trophoblastic tissues (Figure 1 ), while the syncytiotrophoblast, amniotic epithelium and endothelial cells were MCM7-negative. Occasional weak nuclear staining for MCM7 was noted in stromal cells. The MCM7 indices of each group are tabulated in Table 1 and the statistical results in Table 2 . In normal placentas, early placentas (first trimester) were found to have a higher MCM7 index than in term placenta (P < 0.001). In GTD, MCM7 expression was significantly higher in CCA than in PM and CM (P < 0.001), while there was no statistical difference between PM and CM (P ¼ 0.560). Moreover, MCM7 was significantly higher in PM and CM than in SM (P ¼ 0.007, P < 0.001).
The MCM7 indices of the 18 patients who developed PTD were not significantly different from those of the 47 patients who had spontaneous remission (Table 3) (P ¼ 0.312).
MCM7 expression was found to correlate directly with the proliferation index as assessed by Ki67 (P ¼ 0.002). There was no significant correlation between MCM7 and PCNA (P ¼ 0.054). Moreover, the variation of MCM7 index in each group was in general less than that of Ki67 and PCNA (Table 1) .
Discussion
The present immunohistochemical study was undertaken to determine whether the use of the proliferation All values are expressed as mean ± SD. marker MCM7 would more accurately reflect the proliferation status and would have more discriminatory value to distinguish the various diagnostic categories of gestational trophoblastic disease. Immunoreactivity for MCM7 in normal placentas, SMs, HMs and CCAs was largely confined to the cytotrophoblast but not to the syncytiotrophoblast. This pattern concurs with previous findings that have identified the cytotrophoblast as the major proliferating trophoblast based on Ki67 and PCNA staining. 3, [5] [6] [7] 24, 25 In this study, we observed significant differences between the MCM7 indices of first trimester and term placentas. These findings confirm that there is active growth of the trophoblast in the first trimester placenta, and that such villous trophoblast growth is much diminished in the term placenta. 6, 26 Thus, MCM7 expression seems to correlate well with the expected proliferative activity of the normal placenta.
When the MCM7 indices of SM with hydropic change, PM, CM and CCA were compared, we found that CCA had a distinctively higher proliferation rate than the other three groups, consistent with its malignant neoplastic nature. Moreover, PM and CM had statistically significant higher MCM indices than hydropic miscarriage, which may help to discriminate molar from non-molar trophoblast. Previous studies investigating the proliferation rate of trophoblast, especially those using PCNA immunostaining, have generated considerable controversy. Suresh et al., 7 Jeffers et al., 24 Schammel and Bocklage 3 and our team 5 reported that the PCNA index had limited use in differentiating molar and non-molar trophoblast or CM from PM and could not be applied as a reliable marker for predicting the outcome of HM. In contrast, Ostrzega et al., 4 Ozbilim et al. 27 and Kale et al. 28 observed significant differences in the PCNA index between PM and CM. Ozbilim et al. 27 and Molykutty et al. 29 even noted that PCNA was useful for predicting PTD. Such discrepancies may be, at least in part, due to the inherent problems with PCNA 12 and the different methods used for assessing immunostaining. From the higher proliferative indices and smaller standard deviation values of our immunohistochemical assessment, we demonstrated that MCM can identify a higher proportion of cells than both PCNA and Ki67 with less variability. This pattern has also been observed in previous studies involving a range of human malignancies. 18, 19 One interpretation of this observation is that Ki67 cannot reliably label all proliferating cells. The pattern of Ki67 expression is known to vary through the cell cycle and may not be expressed in cells entering G 1 from G 0 . 30 Hence the likelihood of detecting proliferation by immunohistochemistry may vary. A major advantage of studying the MCM proteins is that the replicative complex is necessary for DNA replication and represents a convergence point for many signalling pathways. 31 In addition, antibodies against MCM proteins do not detect cells undergoing DNA repair, which is a feature of PCNA. 10, 11 Taken together, it seems that MCM is more effective at demonstrating abnormal cycling cells than either Ki67 or PCNA. It is supported by our finding that MCM immunoreactivity could distinguish molar from non-molar trophoblast whilst neither PCNA nor Ki67 were able to do this in our previous studies. Recent studies have shown that immunocytochemical analysis of MCM expression can sensitively detect colorectal cancer in stools, cervical cancer in cervical smears and genitourinary tract cancer in urine sediments. 17, 32, 33 There are few reliable biological markers, besides serial hCG assay, that have been found to be useful in predicting the development of PTD in patients with HM. Our previous studies on the expression of PCNA and Ki67 in HM showed that these proliferation indices are not useful in predicting the progression of molar pregnancies to PTD. 5, 6 In this study, although MCM7 was apparently a more sensitive and specific marker than PCNA and Ki67, it also failed to show a correlation with PTD. Thus, proliferative indices are probably not useful in establishing the prognosis of molar pregnancies, as observed in previous studies using PCNA or Ki67 [3] [4] [5] [6] 24, 26 in contrast to the predictive value of apoptotic activity in GTD demonstrated in our earlier studies. 34, 35 In summary, we have studied MCM7 expression in a retrospective series of GTD and confirmed that MCM proteins are superior to PCNA and Ki67 as proliferation markers. An antibody to MCM7 is more suitable than Ki67 and PCNA in differentiating hydropic miscarriage from hydatidiform moles. However, PM and CM cannot be distinguished from each other by such analysis. Moreover, the MCM7 index does not appear to be useful in predicting the prognosis of molar pregnancies.
